By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sosei Group Corporation 

4F Ichiban-cho FS Building
8 Ichiban-cho, Chiyoda-ku
Tokyo    102-0082  Japan
Phone: 81-0-3-5210-3290 Fax: 81-0-3-5210-3291


SEARCH JOBS








Company News
G2B Pharma Receives Project Financing From Sosei Group Corporation And Right To In-License Nasal Delivery Technologies From SNBL 8/13/2014 7:19:31 AM
Sosei Group Corporation Signs Distribution Agreement With FUJIFILM Pharma For Commercialization Of SO-1105 2/4/2014 9:15:33 AM
Sosei Group Corporation: Once-Daily Ultibro® Inhalation Capsules (QVA149) For COPD Launched In Japan 11/20/2013 9:36:38 AM
Sosei Group Corporation's First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Approved for the Treatment of COPD in Europe 9/23/2013 9:44:18 AM
Sosei Group Corporation: First in Class Once-Daily Dual Bronchodilator Ultibro Inhalation Capsules (QVA149) Approved for the Treatment of COPD in Japan 9/20/2013 10:14:33 AM
Sosei Group Corporation Announces Initiation of Phase III Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis 3/12/2013 10:00:41 AM
Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149 9/4/2012 11:52:42 AM
Sosei Group Corporation Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis 7/2/2012 9:28:38 AM
Sosei Group Corporation Release: Once-daily Seebri® Breezhaler® Receives Positive CHMP Opinion to Treat COPD Patients in the EU 6/25/2012 11:55:44 AM
Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149 4/24/2012 6:52:33 AM
123
//-->